ENDPOINTS

Acelyrin, Pliant turn to ‘poison pill’ as Kevin Tang’s Concentra pursues both companies

Acelyrin and Pliant Therapeutics, both of which are viewed as takeover targets for Kevin Tang’s Concentra Biosciences, each adopted a “poison pill” on Thursday morning. Acelyrin, a struggling immunology biotech that’s faced several clinical setbacks ...

Mar 13, 2025 - 15:51
 0
Acelyrin, Pliant turn to ‘poison pill’ as Kevin Tang’s Concentra pursues both companies
Acelyrin and Pliant Therapeutics, both of which are viewed as takeover targets for Kevin Tang’s Concentra Biosciences, each adopted a “poison pill” on Thursday morning. Acelyrin, a struggling immunology biotech that’s faced several clinical setbacks ...
Read More

Tags:

Previous Article

Electromagnetic fields and dinosaur choir win international instrument contest

Next Article

Breathe Deep, America. Carbon Dioxide Is Good For You!

Related Posts

Gilead plans to skip from Phase 1 to Phase 3 with once-yearly PrEP drug

Gilead plans to skip from Phase 1 to Phase 3 with once-...

Mar 11, 2025  0

DOGE shutters lease on FDA lab in St. Louis and 29 other sites

DOGE shutters lease on FDA lab in St. Louis and 29 othe...

Mar 4, 2025  0

FDA blocks drug and device reviewers from taking HHS' buyout offer

FDA blocks drug and device reviewers from taking HHS' b...

Mar 10, 2025  0